Antibody Secreting Cell and Cyotokine Profiles in Neonates on ECMO
Antibody Secreting Cell (ASC) and Immunoactive Protein Profiles in Neonates on Extracorporeal Membrane Oxygenation (ECMO)
1 other identifier
observational
12
1 country
1
Brief Summary
Infants are placed on ECMO for correction of reversible respiratory failure. Often, because a few of the reasons for respiratory failure show us similar things in the baby, it is difficult to determine exactly which is causing the biggest problem. We are now capable of measuring certain cells and proteins in these infants that may help us more accurately diagnose the exact problem. We hypothesize that infants placed on ECMO will show unique antibody-secreting cells responses and patterns of cytokine and chemokine (protein) response to illness and to the ECMO circuit. If we find unique patterns to these cells or proteins, they may be able to predict outcomes or guide treatment of these infants.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2006
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 30, 2006
CompletedStudy Start
First participant enrolled
September 1, 2006
CompletedFirst Posted
Study publicly available on registry
September 4, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2007
CompletedNovember 5, 2020
November 1, 2020
August 30, 2006
November 3, 2020
Conditions
Keywords
Eligibility Criteria
Infants requiring ECMO
You may qualify if:
- \) term newborn infants \>24 hours and ≤ 30 days old 2) Placed on ECMO in the NICU at MHCH 3) Parental consent obtained within 48 hours of being placed on ECMO
You may not qualify if:
- \) Infant \> 30 days old 2) Infant NOT on ECMO 3) Withdrawal of parental consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Memorial Hermann Hospital
Houston, Texas, 77030, United States
Related Publications (4)
Stoll BJ, Lee FK, Hale E, Schwartz D, Holmes R, Ashby R, Czerkinsky C, Nahmias AJ. Immunoglobulin secretion by the normal and the infected newborn infant. J Pediatr. 1993 May;122(5 Pt 1):780-6. doi: 10.1016/s0022-3476(06)80026-0.
PMID: 8496761BACKGROUNDStoll BJ, Lee FK, Larsen S, Hale E, Schwartz D, Rice RJ, Ashby R, Holmes R, Nahmias AJ. Clinical and serologic evaluation of neonates for congenital syphilis: a continuing diagnostic dilemma. J Infect Dis. 1993 May;167(5):1093-9. doi: 10.1093/infdis/167.5.1093.
PMID: 8486942BACKGROUNDBaqar S, Nour El Din AA, Scott DA, Bourgeois AL, Mourad AS, Kleinosky MT, Oplinger MJ, Murphy JR. Standardization of measurement of immunoglobulin-secreting cells in human peripheral circulation. Clin Diagn Lab Immunol. 1997 May;4(3):375-9. doi: 10.1128/cdli.4.3.375-379.1997.
PMID: 9144380BACKGROUNDKuster H, Weiss M, Willeitner AE, Detlefsen S, Jeremias I, Zbojan J, Geiger R, Lipowsky G, Simbruner G. Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet. 1998 Oct 17;352(9136):1271-7. doi: 10.1016/S0140-6736(98)08148-3.
PMID: 9788457BACKGROUND
Biospecimen
Plasma and whole blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
James M Murpy, PhD
University of Texas Health Science Center at Houston- Division of Infectious Diseases
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
August 30, 2006
First Posted
September 4, 2006
Study Start
September 1, 2006
Study Completion
November 1, 2007
Last Updated
November 5, 2020
Record last verified: 2020-11